Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Development of a novel detection technology for drug resistance mutation sites of Mycobacterium tuberculosis using Luminex liquid chip technology

Changjiang Liu¹, Mingliang Tang², Liyuan Zhang³, Yi Huang⁴, Naihui Chu¹

¹Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing; ²Department of Gastroenterology; ³Department of Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University; ⁴Hainan Medical University, The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, The University of Hong Kong, Haikou, China.

For correspondence:- Naihui Chu Email: lcj20062052@126.com

Accepted: 11 November 2022 Published: 29 December 2022

Citation: Liu C, Tang M, Zhang L, Huang Y, Chu N. Development of a novel detection technology for drug resistance mutation sites of Mycobacterium tuberculosis using Luminex liquid chip technology. Trop J Pharm Res 2022; 21(12):2639-2644 doi: 10.4314/tjpr.v21i12.19

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop a novel detection technology for drug-resistance mutation sites of Mycobacterium tuberculosis (MTB) using a Luminex liquid chip.

Methods: Using polymerase chain reaction (PCR) amplification and hybridization analysis, MTB infection and drug-resistant mutation sites of the first-line and second-line anti-MTB drugs were simultaneously identified. A novel detection method was applied to analyze the wild-type standard strains of MTB and 33 clinical samples, and the results were compared with Sanger sequencing results for PCR products.

Results: It was revealed that the sensitivity (100 %) and specificity (100 %) of the novel detection method for 31 samples were satisfactory, and all mutation sites were correctly detected. Compared with traditional PCR and culture-based drug sensitivity test, the novel detection method increased the speed of identification of drug-resistant TB, reduced clinicians' workload, and decreased treatment cost. Among 31 samples, 12.90 % were resistant to isoniazid (4/31), 35.48 % to rifampicin (11/31), and 12.90 % to ofloxacin (p < 0.05). Furthermore, 2 (6.45 %) samples were resistant to both isoniazid and rifampicin, 2 (6.45 %) samples to both rifampicin and ofloxacin, and 1 (3.22 %) sample to both isoniazid and ofloxacin, and 1 (3.22%) sample to all the three drugs (p < 0.05).

Conclusion: Development and wide application of this novel detection method will facilitate the treatment of MTB, thus reducing the spread of drug-resistant MTB, and improving the prevention and treatment of MTB.

Keywords: Luminex liquid chip technology, Mycobacterium tuberculosis, Drug-resistant mutation, Polymerase chain reaction